Lineage Cell Therapeutics (LCTX) Capital Expenditures Growth (3y) (2013 - 2026)
Lineage Cell Therapeutics (LCTX) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -12.25% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn | -28.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.90% |
| Dec 31, 2025 | 47.96% |
| Sep 30, 2025 | -32.01% |
| Jun 30, 2025 | -47.55% |
| Mar 31, 2025 | 28.23% |
| Dec 31, 2024 | 55.97% |
| Sep 30, 2024 | -50.75% |
| Jun 30, 2024 | -27.09% |
| Mar 31, 2024 | 51.17% |
| Dec 31, 2023 | 55.93% |
| Sep 30, 2023 | 79.58% |
| Jun 30, 2023 | 264.68% |
| Mar 31, 2023 | 148.25% |
| Dec 31, 2022 | -289.93% |
| Sep 30, 2022 | 60.63% |
| Jun 30, 2022 | -20.77% |
| Mar 31, 2022 | -35.19% |
| Dec 31, 2021 | -31.79% |
| Sep 30, 2021 | -30.66% |
| Jun 30, 2021 | 49.00% |